USPTO Patent Applications - Pharma (A61K)

Pouch Dispensing System for Topical Anesthetic

USPTO published patent application US20260090987A1 for a pouch dispensing system for topical anesthetic. Invented by Andrew Albee, the application (No. 19347190, filed 2025-10-01) covers an apparatus including a pouch, cover material, and topical anesthetic for oral application.

Tablet Formulation Patent for HIV Capsid Inhibitor and NRTTI

The USPTO published patent application US20260090994A1 for tablet formulations combining an HIV capsid inhibitor with a nucleoside reverse transcriptase translocation inhibitor (NRTTI) for treating HIV infections. The application was filed on August 29, 2025 under Application No. 19314157. Inventors include Benjamin Chal, Jay Poorna Reddy, Dhananjay Devidas Marathe, and eight others.

Pharmaceutical Compositions Comprising Maralixibat and Uses Thereof

The USPTO published patent application US20260090993A1 by Mirum Pharmaceuticals, Inc. for pharmaceutical compositions comprising maralixibat as an active ingredient. The application covers the use of these compositions as solid dosage drug products for treating cholestatic pruritus and cholestatic liver disease. The application was filed on April 9, 2025, and contains 8 CPC classifications related to drug formulations.

Cosmetic Base Patent with Polymer Formula for Moisturizing Effect

Shiseido Company, Ltd. filed USPTO Patent Application US20260090976A1 for a cosmetic base composition containing a polymer formula designed to provide both use sensation and moisturizing effect. The polymer has a number-average molecular weight not exceeding 10,000 and an IOB value between 0.4 and 1.8. The application was published on April 2, 2026 with Filing Date August 31, 2023.

Water-in-oil cosmetic composition

USPTO published patent application US20260090977A1 for a water-in-oil cosmetic composition comprising specific silicone components (A) and (B) along with silicone powder (C), designed to improve stability, spreadability, and layered makeup durability. The application was filed September 7, 2023, with inventors Masaru Miyauchi, Masayuki Konishi, Yoshinori Inokuchi, and Ryuji Horiguchi.

Mascara Composition with Sunflower Seed Wax

L'ORÉAL published patent application US20260090978A1 for mascara composition containing sunflower seed wax, tribehenin, and behenyl behenate. The invention provides improved aesthetics with total wax content of 5-35% by weight and combined wax blend of 5-20%. Application filed September 2024 with inventors David CHAN and Geoffrey WHITE.

Cosmetic Uses of Phaeodactylum Tricornutum Hydrolysate

USPTO published patent application US20260090979A1 by MICROPHYT covering cosmetic uses of a hydrolysate derived from an ethanolic extraction coproduct of the microalgae Phaeodactylum tricornutum. The invention targets skin exfoliation and reduction of skin microrelief for cosmetic and nutraceutical applications.

Cosmetic Compositions for Skin Firming Using Escin Extracts

USPTO published Mary Kay Inc.'s patent application for cosmetic compositions containing escin and botanical extracts for treating sagging, loose skin and improving facial contouring. The application includes methods comprising topical application of compositions with escin, Ascophyllum nodosum extract, caffeine, Coleus barbatus extract, and other plant-based ingredients. This is an informational publication with no regulatory compliance requirements.

Transdermal Delivery Formulations

USPTO published patent application US20260090981A1 for LifeActive, Inc., covering transdermal delivery formulations combining weak organic acids with fatty acid microemulsions for epicutaneous administration of therapeutic agents, drugs, and nutrients. The formulations are designed for use in high humidity conditions such as showers or saunas.

Pediatric parenteral nutrition, oil-in-water emulsion, multi-chamber containers

USPTO published patent application US20260090983A1 for pediatric parenteral nutrition formulations comprising lipid emulsions in oil-in-water form. The application also covers multi-chamber containers for separating carbohydrate, amino acid, and lipid formulations until administration. Inventors include Jean-Luc Trouilly, Mary Hise Brown, Laurent Jeannin, Julien Hecq, and Julie Fahier.

Contact Lenses with Medicament Coating for Drug Release in Glaucoma Treatment

MEDIPRINT OPHTHALMICS INC. filed patent application US20260090984A1 for contact lenses incorporating medicament coatings for controlled drug release, specifically targeting glaucoma treatment through sustained delivery of drugs such as bimatoprost. The application covers the lens composition including N-vinylpyrrolidone, soaking solutions, and methods for loading and refreshing drug-eluting contact lenses. This patent application (No. 19411056, filed December 5, 2025) names six inventors including Praful Doshi and Brandon Huang.

Composition for Promoting the Skin Microbiome

USPTO published patent application US20260090967A1 for a skin microbiome promoting composition. The application claims a combination of carbon sources (glucose, fructose, saccharose, maltose, maltodextrin, pyruvic acid, pyruvate, lactic acid and lactate) and nitrogen sources (alanine, glycine, arginine and urea), and/or caprylic/capric triglycerides. Inventors include Jennifer Huepeden, Mirja Laschet, Karen Tom Dieck, Heike Foelster, and Sabine Sellckau.

Cellular Oxidative and Mitochondrial Stress Protection Compositions

NUCHIDO LIMITED filed USPTO Patent Application US20260090969A1 for compositions protecting cells from oxidative and mitochondrial stress. The application discloses a combination of bioactive compounds including NMN, NR, resveratrol, curcumin, and other cellular stress protectors for pharmaceutical and cosmetic applications. Published April 2, 2026.

Sodium DNA Lipid Nanoparticle Drug Delivery Patent

USPTO published patent application US20260090968A1 for a lipid nanoparticle composition containing sodium DNA as an active ingredient, with applications in pharmaceutical drug delivery systems. The composition includes sodium dilauramidoglutamide lysine as an amphiphilic surfactant, distearoylphosphatidylcholine as an auxiliary surfactant, cholesterol as a stabilizer, and auxiliary stabilizers including PEG-120 stearate, polyglyceryl-4 caprate, and PEG-PCL copolymer. Filing date is October 10, 2023.

Composition Comprising Biosurfactant and Salicylic Acid

USPTO published L'OREAL's patent application for a skincare composition combining glycolipid biosurfactants with salicylic acid derivatives, cationic polymers, and clay for treating acne-prone skin. The application, filed September 30, 2024, covers formulations with water and glycerin solvents for topical use.

Xanthommatin Color Additive for Food Beverage and Drug Compositions

USPTO published patent application US20260090963A1 by inventor Leila Deravi for xanthommatin as an edible color additive for food, beverage, and drug compositions at 0.01-0.5% wt concentration. The application covers substrates including foods, beverages, drinks, medications, and drug forms.

Hydrophobic Cellulose Powder for Cosmetic Applications

USPTO published patent application US20260090962A1 for surface-treated hydrophobic cellulose powder. The invention uses modified dextrin and/or modified amino acids to render cellulose powders hydrophobic, improving dispersibility, feel, and stability. The powders are intended for cosmetic applications including foundations, skin care, and hair care products.

Antiperspirant Cream Patent Application by Lume Deodorant LLC

The USPTO published patent application US20260090961A1 by Lume Deodorant, LLC for an antiperspirant cream composition containing water, an antiperspirant material, alpha-hydroxycarboxylic acid, an oil agent, and a structuring agent, with optional caffeine or xanthine derivatives. The application was filed on September 27, 2024, and names inventors Shannon Klingman, Stephanie Richmond, Rebecca Reynandez, and Nikita Bhatnagar. This is an informational publication of a patent application; no regulatory compliance obligations are created.

Vital Pulp Therapy Using Bioactive Composites

USPTO published patent application US20260090960A1 by Imam Abdulrahman Bin Faisal University for a method of vital pulp therapy using a bioactive capping material. The invention comprises a mixture of glass ionomer cement (GIC) and potassium nitrate (KNO3) in 1-10 wt.% concentration with a solvent. The application was filed September 30, 2024.

Process for Making Aqueous Therapeutic Particles with Nanosized Water Clustering

USPTO published patent application US20260090957A1 for a process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering between 1-300 nanometers. The invention, assigned to a multi-inventor team, claims improved bioavailability for therapeutic compositions including CBD, PNC-27 peptides, pharmaceuticals, and nutraceuticals through a computer-controlled continuous manufacturing process.

Depilatory Emulsion Containing Paclitaxel and Preparation Method

USPTO published patent application US20260090965A1 for a depilatory emulsion containing paclitaxel by inventor Ming Xia. The invention comprises 10-20% oil, 8-12% humectant, 4-6% emulsifiers, 8-12% paclitaxel solution, and auxiliary ingredients, designed to target hair follicles while preventing dermal absorption. A stepwise cooling and gradual emulsification method ensures stable emulsion formation.

USPTO Patent Application for Compounds Targeting Pax3/Foxo1 Fusion Protein

The USPTO has published patent application US20260083724A1, filed by Georgetown University, for novel compounds designed to target the PAX3::FOXO1 fusion protein. These compounds aim to reduce protein levels and treat fusion-positive rhabdomyosarcoma.

Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment

The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.

Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents

The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.

Biopolymers for Ophthalmic Use Patent Application

The USPTO has published a patent application (US20260083771A1) for biopolymers intended for ophthalmic use, filed by ExoPolymer, Inc. The application details biopolymers comprising repeating polysaccharide units, their preparations, ophthalmic compositions, and methods of use.

Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083772A1) for powder compositions comprising fiber intended for use as a prebiotic dietary supplement. The application details therapeutic ingredients and manufacturing processes aimed at improving gut microbiome and overall gut health.

Pegylated Menaquinol Compositions and Treatment Methods Patent Application

The USPTO has published a patent application (US20260083773A1) for pegylated menaquinol compositions and methods of treatment. The application, filed on December 5, 2025, discloses isolated, stable, and biologically active pegylated menaquinol derivatives for treating various diseases.

Metal nanoparticle agglomerates for infection control and water purification

The USPTO has published a patent application detailing the use of metal nanoparticle agglomerates for infection control and water purification. The application describes antiseptic substrates and fluid formulations incorporating these agglomerates for topical or oral use, aiming to provide infection control against infective agents.

Patent Application: Cytotoxic Lymphocyte Activation and Expansion

The USPTO has published patent application US20260083776A1 concerning methods for activating and expanding cytotoxic lymphocytes with decreased exhaustion potential. The application details micropatterned surfaces and biofunctionalization techniques for cell expansion, potentially impacting future therapeutic development in oncology.

Patent Application: Acetic Acid and Hypochlorous Acid Compositions for Skin Trauma Treatment

The USPTO has published a new patent application (US20260083774A1) detailing compositions containing hypochlorous acid and acetic acid for treating skin trauma and biofilms. The application was filed on September 22, 2025, and published on March 26, 2026.

Immunity Enhancing Composition with Amide Compound

The USPTO has published a patent application (US20260083715A1) for a composition containing a novel amide-based compound derived from amino acids. The composition is designed to enhance immunity by activating macrophage phagocytosis, aiding in the removal of pathogenic bacteria.

R-Trihexyphenidyl Patent for Movement Disorder Treatment

The USPTO has published a new patent application, US20260083716A1, filed by The Children's Mercy Hospital. The patent covers compositions and methods for treating movement disorders, such as dystonia, using high chiral purity R-trihexyphenidyl.

Deuterated Domperidone Formulations for Gastroparesis and Nausea

The USPTO has published a patent application (US20260083717A1) for deuterated domperidone formulations. These formulations are intended for treating gastroparesis, nausea, vomiting, and other related conditions. The application details specific excipient combinations for these pharmaceutical compositions.

Piperidine Urea Derivatives for Obesity Therapy Patent Application

The USPTO has published a patent application (US20260083718A1) filed by Astrizi Bio, Inc. The application describes piperidine urea derivatives for preventing, suppressing, or treating obesity, potentially in combination with GLP-1 receptor agonists.

USPTO Patent Application for Improving Sperm Quality

The USPTO has published a patent application (US20260083719A1) filed by The University of Adelaide for methods and products aimed at improving sperm quality. The application details the use of specific compounds, such as BGP-15, in assisted reproductive technologies.

Patent Application: Childhood Atropine Formulation for Myopia Progression

The USPTO has published a patent application (US20260083720A1) filed by Vyluma Inc. for a storage-stable, low-dose atropine formulation (0.01%) intended to reduce myopia progression in children. The application details the formulation's unexpected effectiveness compared to a higher concentration.

Therapeutic Agent for ALS Inhibits Ferroptosis Using Tetrahydroquinoline Derivative

The USPTO has published a patent application (US20260083723A1) from Toray Industries, Inc. The application describes a therapeutic or preventive agent for amyotrophic lateral sclerosis (ALS) that inhibits ferroptosis, utilizing a tetrahydroquinoline derivative as the active ingredient. This filing details compositions and methods for treating ALS and inhibiting ferroptosis.

Dosing regimen for treating PKU with piperidine inhibitor

The USPTO has published a new patent application (US20260083714A1) detailing a dosing regimen for treating phenylketonuria (PKU) using a piperidine inhibitor of SLC6A19 function. The application was filed on August 25, 2023, by inventors John Peter Throup and Heather Smith Blanchette.

Novel LXR Modulators with Bicyclic Core for Treating Dyslipidemias

The USPTO has published a new patent application, US20260083704A1, detailing novel LXR modulators with a bicyclic core for treating dyslipidemias and related metabolic disorders. The application was filed on May 1, 2025, and published on March 26, 2026.

USPTO Patent Application for Transdermal Dexmedetomidine

The USPTO has published patent application US20260083705A1 for methods of using transdermal delivery patches containing dexmedetomidine to treat agitation. The application was filed on September 24, 2025, by inventors Wan-Ning Song and Gary G. Kay.

Patent Application: Methods for treating epilepsy using 5HT receptor agonists

The USPTO has published a new patent application (US20260083706A1) detailing methods for treating epilepsy using 5HT receptor agonists. The application was filed on May 29, 2025, by inventor Scott C. Baraban.

Tinostamustine for T-cell prolymphocytic leukemia treatment patent

The USPTO has published a patent application (US20260083707A1) for Purdue Pharma L.P. detailing the use of tinostamustine for treating T-cell prolymphocytic leukemia. The application was filed on July 28, 2025.

Patent Application: Compounds for Inhibiting IL-17

The USPTO has published a patent application (US20260083708A1) detailing compounds for inhibiting IL-17 activity. The application, filed on December 1, 2025, describes compounds and methods for treating inflammatory and autoimmune disorders.

Patent Application: Combination Pharmacological Interventions for Sleep Apnea

The USPTO has published patent application US20260083709A1, detailing a novel pharmacological intervention for treating obstructive sleep apnea. The application, filed on December 3, 2025, describes pharmaceutical compositions involving a combination of a norepinephrine reuptake inhibitor, muscarinic receptor antagonist, and carbonic anhydrase inhibitor.

USPTO Patent Application for Acute Migraine Treatment with Ubrogepant

The USPTO has published a new patent application (US20260083710A1) detailing methods for the acute treatment of migraine using the drug ubrogepant. The application includes specific claims related to treatment in patients with hepatic or renal impairment and those concurrently taking certain CYP3A4 modulators or BCRP/P-gp inhibitors.

Patent for treating ocular autoimmune disorder comorbidities with roflumilast

The USPTO has published a new patent application (US20260083712A1) assigned to Iolyx Therapeutics, Inc. The patent describes methods for treating ocular comorbidities of autoimmune disorders, such as dry eye disease, using ophthalmic formulations of roflumilast. The application was filed on September 19, 2025.

Multilayered Microparticles for Controlled Release of Active Compounds

The USPTO has published a new patent application (US20260083713A1) detailing multilayered microparticles for controlled release of active compounds in liquid dosage forms. The application was filed on October 21, 2025, by inventors from Belgium.

Method Uses Monoterpene or Sesquiterpene to Permeabilize Blood Brain Barrier

The USPTO has published a patent application detailing a method for permeabilizing the blood-brain barrier using monoterpenes or sesquiterpenes. The application, assigned to the University of Southern California, describes a treatment for central nervous system cancers involving perillyl alcohol and CAR-T cells.

Patent Application for Suppressing Reflux-Induced Protein Adducts

The USPTO has published patent application US20260083686A1, filed on November 24, 2025, by Alexander Zaika and Sergey I Dikalov. The application details methods and compounds for suppressing the accumulation of reflux-induced protein adducts.

USPTO Patent Application for Lactation Reduction Compounds

The USPTO has published a patent application (US20260083687A1) for compounds intended for reducing lactation and improving health. The application, filed on April 14, 2023, lists specific disulfide, sulfide, trisulfide, sulfone, thiosulfinate, and thiosulfonate compounds as preferred embodiments. This represents a new patent filing, not a regulatory rule or guidance.